These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6398243)

  • 1. Cancer cell procoagulants and their pharmacological modulation.
    Donati MB; Semeraro N
    Haemostasis; 1984; 14(5):422-9. PubMed ID: 6398243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?
    Donati MB; Roncaglioni MC; Falanga A; Casali B; Semeraro N
    Haemostasis; 1986; 16(3-4):288-94. PubMed ID: 3530903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
    Roncaglioni MC; Dalessandro AP; Casali B; Vermeer C; Donati MB
    Haemostasis; 1986; 16(3-4):295-9. PubMed ID: 3530904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic insight into the procoagulant activity of tumor-derived apoptotic vesicles.
    Muhsin-Sharafaldine MR; Kennedy BR; Saunderson SC; Buchanan CR; Dunn AC; Faed JM; McLellan AD
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):286-295. PubMed ID: 27864149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of procoagulant factors in mononuclear phagocytes.
    Dean RT; Leoni P; Rossi BC
    Haemostasis; 1984; 14(5):412-21. PubMed ID: 6398242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.
    Marchetti M; Russo L; Balducci D; Falanga A
    Thromb Res; 2011 Oct; 128(4):368-74. PubMed ID: 21458031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer procoagulant in human tumor cells: evidence from melanoma patients.
    Donati MB; Gambacorti-Passerini C; Casali B; Falanga A; Vannotti P; Fossati G; Semeraro N; Gordon SG
    Cancer Res; 1986 Dec; 46(12 Pt 1):6471-4. PubMed ID: 3536081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.
    Kaplinska K; Rozalski M; Krajewska U; Mielicki WP
    Thromb Res; 2009 Jul; 124(3):364-7. PubMed ID: 19419757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency.
    Colucci M; Delaini F; de Bellis Vitti G; Locati D; Poggi A; Semeraro N; Donati MB
    Biochem Pharmacol; 1983 Jun; 32(11):1689-91. PubMed ID: 6870908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
    Zivelin A; Rao LV; Rapaport SI
    J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen regulation of a tissue factor-like procoagulant in the immature rat uterus.
    Jazin EE; Dickerman HW; Henrikson KP
    Endocrinology; 1990 Jan; 126(1):176-85. PubMed ID: 2293981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell prothrombotic properties.
    Falanga A
    Haemostasis; 2001; 31 Suppl 1():1-4. PubMed ID: 11990464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma.
    Inufusa H; Adachi T; Kiyokawa T; Nakatani Y; Wakano T; Nakamura M; Okuno K; Shiozaki H; Yamamoto S; Suzuki M; Ando O; Kurimoto M; Miyake M; Yasutomi M
    Int J Oncol; 2001 Nov; 19(5):941-6. PubMed ID: 11604991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
    Fasco MJ; Wilson AC; Lincoln D; Gierthy J
    Int J Cancer; 1987 May; 39(5):631-7. PubMed ID: 3570555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antihemostatic agents on experimental tumor dissemination.
    Francis JL; Amirkhosravi A
    Semin Thromb Hemost; 2002 Feb; 28(1):29-38. PubMed ID: 11885023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells.
    Lorenzet R; Bottazzi B; Locati D; Colucci M; Mantovani A; Semeraro N; Donati MB
    Eur J Cancer Clin Oncol; 1985 Feb; 21(2):263-5. PubMed ID: 3987761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteolytic procoagulant associated with malignant transformation.
    Gordon SG
    J Histochem Cytochem; 1981 Mar; 29(3A Suppl):457-63. PubMed ID: 7016982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage procoagulants.
    Edwards RL; Rickles FR
    Prog Hemost Thromb; 1984; 7():183-209. PubMed ID: 6397766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice.
    Donati MB
    Thromb Haemost; 1995 Jul; 74(1):278-81. PubMed ID: 8578472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
    Lyberg T
    Haemostasis; 1984; 14(5):430-9. PubMed ID: 6398244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.